Suppliers and packagers for generic pharmaceutical drug: BACLOFEN

BACLOFEN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Strides Pharma Intl	LYVISPAH	baclofen	GRANULES;ORAL	215422	NDA	Amneal Pharmaceuticals LLC	64896-076-09	90 PACKET in 1 CARTON (64896-076-09) / 1 GRANULE in 1 PACKET	2023-06-01
Strides Pharma Intl	LYVISPAH	baclofen	GRANULES;ORAL	215422	NDA	Amneal Pharmaceuticals LLC	64896-077-09	90 PACKET in 1 CARTON (64896-077-09) / 1 GRANULE in 1 PACKET	2023-06-01
Strides Pharma Intl	LYVISPAH	baclofen	GRANULES;ORAL	215422	NDA	Amneal Pharmaceuticals LLC	64896-078-09	90 PACKET in 1 CARTON (64896-078-09) / 1 GRANULE in 1 PACKET	2023-06-01
Maia Pharms Inc	BACLOFEN	baclofen	INJECTABLE;INTRATHECAL	210777	ANDA	Sagent Pharmaceuticals	25021-681-71	2 SYRINGE in 1 CARTON (25021-681-71) / 1 mL in 1 SYRINGE	2021-07-15
Maia Pharms Inc	BACLOFEN	baclofen	INJECTABLE;INTRATHECAL	210777	ANDA	MAlA Pharmaceuticals, Inc.	70511-121-80	2 SYRINGE, GLASS in 1 CARTON (70511-121-80) / 1 mL in 1 SYRINGE, GLASS	2021-04-02
Maia Pharms Inc	BACLOFEN	baclofen	INJECTABLE;INTRATHECAL	210048	ANDA	Sagent Pharmaceuticals	25021-678-20	1 VIAL in 1 CARTON (25021-678-20) / 20 mL in 1 VIAL	2021-07-15

Baclofen API Suppliers: Global Market Landscape and Key Manufacturers

Last updated: February 19, 2026

Baclofen, a muscle relaxant and antispasmodic, relies on a global network of active pharmaceutical ingredient (API) manufacturers to meet market demand. The procurement of baclofen API is critical for generic drug producers and contract manufacturing organizations (CMOs) involved in the formulation of finished dosage forms. This analysis identifies key suppliers, examines their production capacities, and highlights factors influencing market dynamics.

Who are the Primary Manufacturers of Baclofen API?

The production of baclofen API is concentrated among a limited number of global manufacturers, with a significant presence in Asia, particularly China and India. These regions benefit from established chemical synthesis infrastructure and competitive manufacturing costs.

Key manufacturers include:

• Aarti Industries Limited (India): A significant player in the global pharmaceutical intermediates and specialty chemicals market. Aarti Industries has a well-established production base for various APIs, including those in the central nervous system (CNS) therapeutic class. Their manufacturing facilities are compliant with international regulatory standards.
• Hubei Huajing Chemical Co., Ltd. (China): This company is a dedicated producer of pharmaceutical chemicals and APIs. They are known for their focus on bulk drug manufacturing and supply chain integration within the Chinese chemical industry.
• Shaanxi King-Win New Materials Co., Ltd. (China): Specializes in the research, development, production, and sales of pharmaceutical intermediates and APIs. They cater to both domestic and international markets, adhering to quality certifications.
• Changzhou Qutong Chemical Co., Ltd. (China): A chemical enterprise engaged in the production of fine chemicals, pharmaceutical intermediates, and APIs. Their operations often involve custom synthesis and large-scale manufacturing.
• Neuland Laboratories Limited (India): Another Indian pharmaceutical company with a strong focus on API development and manufacturing. Neuland Laboratories offers a portfolio of APIs across various therapeutic segments, with robust quality control systems.
• Solara Active Pharma Sciences Limited (India): Solara is a global producer of APIs and intermediates, with a commitment to quality and regulatory compliance. They serve multiple markets and have a diverse product range.
• Loba Chemie Pvt. Ltd. (India): While also involved in laboratory chemicals, Loba Chemie is a recognized supplier of pharmaceutical raw materials and APIs, including baclofen, to research institutions and manufacturers.

These manufacturers differ in scale, regulatory approvals, and the specific grades of baclofen API they offer (e.g., different particle sizes, purity levels).

What are the Production Capacities and Scale of Operations?

Specific, publicly disclosed production capacities for baclofen API by individual manufacturers are not readily available. However, the market size and the number of suppliers suggest substantial aggregate production. The demand for baclofen is moderate compared to blockbuster drugs, implying that manufacturers operate at scales sufficient to serve the global generic market without necessarily requiring massive, single-site production volumes comparable to high-demand APIs.

Factors influencing perceived scale of operations include:

• Number of Launched Products: Manufacturers supplying to multiple regulated markets (US, EU, Japan) demonstrate a higher level of quality assurance and regulatory compliance, often indicative of more mature and scaled operations.
• Global Reach: Companies with established distribution networks and sales in key pharmaceutical markets indicate a capacity to produce and supply in significant volumes.
• Investment in Facilities: Ongoing investments in modern manufacturing plants and advanced synthesis technologies point to a commitment to sustained and potentially expanded production.
• API Portfolio Diversity: A broad portfolio of APIs may indicate diversified production lines and the flexibility to allocate resources to specific products like baclofen as demand fluctuates.

For example, companies like Aarti Industries and Neuland Laboratories, with extensive portfolios and multiple global regulatory approvals (US FDA, EDQM CEP), are understood to have significant, scalable manufacturing capabilities. Chinese manufacturers, often operating with competitive cost structures, also contribute substantial volume to the global supply chain.

What are the Regulatory and Quality Standards for Baclofen API?

Baclofen API must adhere to stringent regulatory requirements to ensure patient safety and drug efficacy. Key standards and regulatory bodies include:

• United States Pharmacopeia (USP): The USP sets official standards for medicines, including baclofen. Manufacturers must ensure their API meets USP monograph specifications for identity, strength, quality, and purity.
• European Pharmacopoeia (Ph. Eur.): Similar to USP, the Ph. Eur. provides a legal and scientific standard for medicinal substances in Europe.
• International Conference on Harmonisation (ICH) Guidelines: ICH guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), are critical. Adherence demonstrates robust quality management systems.
• Good Manufacturing Practices (GMP): Regulatory agencies worldwide, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), mandate GMP compliance for API manufacturers. This covers all aspects of production, from raw materials to finished API.
• Drug Master Files (DMFs): Manufacturers often submit DMFs to regulatory authorities (e.g., FDA) detailing the chemistry, manufacturing, and controls of their API. This allows drug product manufacturers to reference the DMF in their marketing applications.
• Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP confirms that an API complies with the requirements of the Ph. Eur.

Manufacturers based in India and China often hold US FDA site inspections and CEPs, facilitating their entry into regulated markets. The presence of these certifications is a primary indicator of a supplier's commitment to quality and regulatory adherence.

What are the Key Market Drivers and Challenges for Baclofen API Suppliers?

Several factors influence the market for baclofen API:

Market Drivers:

• Increasing Prevalence of Spasticity Disorders: Conditions such as multiple sclerosis, spinal cord injuries, and cerebral palsy, which lead to spasticity, are primary indications for baclofen. The aging global population and the incidence of these chronic conditions drive demand.
• Growth of Generic Pharmaceuticals: Baclofen is a well-established generic medication. The ongoing demand for affordable healthcare solutions supports the market for generic baclofen tablets and other formulations, thereby sustaining demand for the API.
• Development of New Formulations: While oral tablets are common, research into alternative delivery systems (e.g., intrathecal pumps for severe spasticity) can create niche demand and require specialized API characteristics.
• Export Market Expansion: Emerging markets with developing healthcare infrastructure represent growth opportunities for both API suppliers and finished drug manufacturers.

Market Challenges:

• Price Pressure and Competition: The generic nature of baclofen leads to intense price competition among API manufacturers. This pressure can impact profit margins and necessitate efficient, cost-effective production.
• Regulatory Scrutiny and Compliance Costs: Meeting evolving GMP standards and maintaining regulatory filings (DMFs, CEPs) requires significant investment in quality control, documentation, and facility upgrades. Non-compliance can lead to supply disruptions and loss of market access.
• Supply Chain Disruptions: Geopolitical events, raw material availability, and logistical challenges can disrupt the global supply of APIs. Diversifying sourcing and maintaining robust inventory management are crucial.
• Intellectual Property Landscape: While baclofen itself is off-patent, any novel manufacturing processes or polymorphs could potentially be subject to intellectual property protection, although this is less common for older molecules.
• Environmental Regulations: Increasingly stringent environmental regulations in manufacturing regions can impact production costs and necessitate investments in pollution control technologies.

How do Baclofen API Prices Vary by Region and Supplier?

Baclofen API pricing is influenced by multiple factors:

• Manufacturing Location: Suppliers in China and India generally offer more competitive pricing due to lower labor and operational costs compared to manufacturers in Europe or North America.
• Quality and Regulatory Compliance: APIs produced under strict GMP conditions and holding certifications like US FDA approval or CEPs command higher prices due to the associated quality assurance and market access benefits.
• Volume of Purchase: Bulk purchases typically receive volume discounts. Long-term supply agreements can also secure more stable and potentially lower pricing.
• Purity and Specifications: APIs meeting higher purity standards or specific physical characteristics (e.g., controlled particle size distribution for direct compression) may be priced at a premium.
• Supply Chain Dynamics: Fluctuations in raw material costs, currency exchange rates, and global demand can cause price volatility.

As an example, pricing for non-GMP grade baclofen API for research purposes will be significantly lower than for GMP-certified API intended for commercial pharmaceutical production in regulated markets. A typical market price range for GMP-grade baclofen API can vary broadly, but as of recent data, it might range from approximately $30 to $80 per kilogram, depending heavily on the supplier, volume, and specific regulatory compliance. This is a general estimate and actual negotiated prices will differ.

How to Select a Baclofen API Supplier?

Selecting an appropriate baclofen API supplier is a critical decision for pharmaceutical companies. A systematic approach is recommended:

1. Regulatory Compliance Verification:

   • Confirm GMP certification from relevant authorities (FDA, EMA, etc.).
   • Review DMF status and any associated deficiency letters.
   • Check for CEPs or equivalent certifications for target markets.
   • Request site inspection reports or audit history.

2. Quality Management System Assessment:

   • Evaluate the supplier's Quality Management System (QMS) documentation.
   • Inquire about change control processes, deviation management, and CAPA (Corrective and Preventive Actions) systems.
   • Assess their analytical testing capabilities and validation procedures.

3. Production Capability and Reliability:

   • Understand their manufacturing scale and capacity for baclofen.
   • Assess their track record for on-time delivery and consistency.
   • Inquire about their business continuity and risk management plans (e.g., for raw material sourcing, geopolitical risks).

4. Technical Support and Collaboration:

   • Evaluate their responsiveness to technical queries.
   • Assess their willingness to collaborate on product development or troubleshooting.
   • Inquire about their expertise in baclofen synthesis and characterization.

5. Commercial and Supply Chain Factors:

   • Obtain detailed pricing structures, including volume discounts and payment terms.
   • Understand their supply chain transparency and traceability mechanisms.
   • Discuss contract terms, including force majeure clauses and termination conditions.
   • Consider their financial stability and long-term viability.

A thorough due diligence process, often involving on-site audits, is essential to mitigate risks and ensure a reliable supply of high-quality baclofen API.

Key Takeaways

• Baclofen API manufacturing is primarily concentrated in China and India, with key players like Aarti Industries, Hubei Huajing Chemical, and Neuland Laboratories.
• Regulatory compliance, including GMP, USP/Ph. Eur. standards, and DMF filings, is paramount for suppliers serving regulated markets.
• Market drivers include the prevalence of spasticity disorders and the demand for generic medications.
• Challenges involve intense price competition, stringent regulatory oversight, and supply chain volatility.
• Supplier selection requires rigorous assessment of regulatory compliance, quality systems, production reliability, and commercial terms.

Frequently Asked Questions

1. What is the typical lead time for ordering GMP-grade baclofen API from major suppliers? Lead times can vary significantly but generally range from 6 to 12 weeks for established products from reputable suppliers, assuming standard order volumes. This can extend for custom orders or in periods of high demand.

2. Are there specific impurities of concern in baclofen API that manufacturers must control? Yes, regulatory bodies require strict control of impurities. For baclofen, specific attention is paid to process-related impurities and degradation products, with limits defined by pharmacopoeial monographs (USP, Ph. Eur.) and ICH guidelines. Manufacturers must identify, quantify, and control these.

3. Does the physical form of baclofen API (e.g., particle size) impact its suitability for different drug formulations? Yes. Particle size distribution is critical, especially for solid oral dosage forms. For direct compression tablet manufacturing, a controlled particle size is often preferred to ensure uniform blend content and good flowability. Micronization or specific crystallization processes may be employed to achieve desired characteristics.

4. What is the typical shelf life of baclofen API, and how is it determined? The shelf life of baclofen API is typically determined through formal stability studies conducted under ICH conditions. These studies assess the API's stability over time when stored under specified conditions. A common shelf life may range from 2 to 5 years, but this is manufacturer-specific and depends on the packaging and storage conditions.

5. Can baclofen API be sourced from manufacturers outside of China and India? While the majority of high-volume production occurs in China and India due to cost efficiencies, some API manufacturers in Europe and North America may also produce baclofen, particularly for specialized markets or if they have existing integrated production chains. However, these sources may be at a higher price point.

Citations

[1] Aarti Industries Limited. (n.d.). Active Pharmaceutical Ingredients. Retrieved from aartiindustries.com

[2] Hubei Huajing Chemical Co., Ltd. (n.d.). Products. Retrieved from huajingchem.com

[3] Shaanxi King-Win New Materials Co., Ltd. (n.d.). Pharmaceutical Intermediates & APIs. Retrieved from kwcnm.com

[4] Changzhou Qutong Chemical Co., Ltd. (n.d.). Pharmaceutical Intermediates. Retrieved from qutongchem.com

[5] Neuland Laboratories Limited. (n.d.). APIs. Retrieved from neulandlabs.com

[6] Solara Active Pharma Sciences Limited. (n.d.). Products. Retrieved from solara.in

[7] Loba Chemie Pvt. Ltd. (n.d.). Pharmaceuticals. Retrieved from lobachemie.com

[8] United States Pharmacopeia. (n.d.). Monographs. Retrieved from usp.org

[9] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificates of Suitability. Retrieved from edqm.eu

[10] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from ich.org